Related Experiment Video

Updated: Jan 2, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.5K

Gö6983 attenuates breast cancer-induced osteolysis by the apoptotic pathway

Zhiwei Luan1, Jia Li2, Xing Huang3

  • 1Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, China.

Cell Biology International
|December 10, 2019
PubMed

Insights

Gö6983, a protein kinase C inhibitor, effectively inhibits breast cancer bone metastasis and osteolysis in mice. This drug promotes cancer cell death via the mitochondrial apoptosis pathway, offering a potential new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer bone metastasis causes severe complications, impacting survival and quality of life.
  • Osteolysis, a key feature of bone metastasis, exacerbates patient outcomes.
  • Protein kinase C (PKC) signaling is implicated in cancer progression and bone resorption.

Purpose of the Study:

  • To investigate the efficacy of Gö6983, a PKC inhibitor, in a mouse model of breast cancer bone metastasis.
  • To elucidate the mechanisms by which Gö6983 affects breast cancer growth and osteolysis.
  • To evaluate Gö6983's potential as a therapeutic agent for breast cancer-induced bone disease.

Main Methods:

  • Utilized the MDA-MB-231 breast cancer cell line to induce bone metastasis in a mouse model.
  • Administered Gö6983 to assess its impact on tumor growth and osteolysis.
  • Analyzed the effects of Gö6983 on cancer cell apoptosis, specifically focusing on the mitochondrial pathway.

Main Results:

  • Gö6983 demonstrated a significant inhibitory effect on breast cancer progression in the bone metastasis model.
  • Treatment with Gö6983 promoted apoptosis in cancer cells through the mitochondrial pathway.
  • Gö6983 showed a potential to inhibit osteoclast activation, a key process in osteolysis.

Conclusions:

  • Gö6983 exhibits therapeutic potential for managing breast cancer bone metastasis and associated osteolysis.
  • The drug's mechanism involves promoting cancer cell apoptosis via the mitochondrial pathway.
  • Gö6983 may offer a novel strategy for targeting osteoclast activation in breast cancer treatment.
Keywords:
Gö6983RANKLosteoclastprotein kinase C

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.2K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
13.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.9K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.3K